🔥🐔 BizChicken 🐔🔥

Companies Similar to Longboard Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Athira Pharma, Inc.

Athira Pharma, Inc. logo
Market Cap: Lowest
Employees: Low

ATH-1017

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.

Tags: Alzheimer's disease, Parkinson's disease, biopharmaceutical, clinical trials, neurodegeneration

Symbol: ATHA

Recent Price: $0.55

Industry: Biotechnology

CEO: Dr. Mark J. Litton M.B.A., Ph.D.

Sector: Healthcare

Employees: 65

Address: 18706 North Creek Parkway, Bothell, WA 98011

Phone: 425 620 8501

Last updated: 2024-12-31

Entero Therapeutics, Inc.

Entero Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

latiglutenase

First Wave Bio Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and non-systemic therapies for gastrointestinal diseases, including treatments for celiac disease, fat digestion, gastroparesis, and inflammatory bowel diseases.

Tags: biopharmaceutical, celiac disease, gastrointestinal diseases, inflammatory bowel diseases

Symbol: ENTO

Recent Price: $0.62

Industry: Biotechnology

CEO: Mr. James R. Sapirstein M.B.A., R.Ph.

Sector: Healthcare

Employees: 9

Address: 777 Yamato Road, Boca Raton, FL 33431

Phone: (561) 589-7020

Last updated: 2024-12-31

Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Lowest

LP352

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines for neurological diseases. Its lead product candidate, LP352, is in a clinical trial for treating seizures associated with developmental and epileptic encephalopathies. Based in La Jolla, California, the company was formerly known as Arena Neuroscience, Inc.

Tags: California, LP352, biopharmaceutical, clinical-stage, encephalopathies, neurological diseases, seizures, therapies

Symbol: LBPH

Recent Price: $59.98

Industry: Biotechnology

CEO: Mr. Kevin R. Lind

Sector: Healthcare

Employees: 50

Address: 4275 Executive Square, La Jolla, CA 92037

Phone: 619 592 9775

Last updated: 2024-12-31

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

LB-100 series and LB-200 series

Lixte Biotechnology Holdings, Inc. is a drug discovery company leveraging biomarker technology to develop enzyme-targeting drugs for cancer, vascular, metabolic, hereditary, and neurodegenerative diseases.

Tags: biomarker technology, biotechnology, cancer treatment, drug discovery, enzyme targets

Symbol: LIXT

Recent Price: $2.00

Industry: Biotechnology

CEO: Mr. Bastiaan van der Baan M.Sc.

Sector: Healthcare

Employees: 3

Address: 680 East Colorado Boulevard, Pasadena, CA 91101

Phone: 631 830 7092

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. logo
Market Cap: Lowest
Employees: Lowest

LP-10, LP-310

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing drugs by reformulating active agents in existing generic drugs for various applications, including LP-10 for radiation-induced hemorrhagic cystitis and LP-310 for oral lichen planus.

Tags: biotechnology, clinical-stage, drug development, hemorrhagic cystitis, oral lichen planus, pharmaceuticals, reformulation

Symbol: LIPO

Recent Price: $3.12

Industry: Biotechnology

CEO: Dr. Jonathan Kaufman M.B.A., Ph.D.

Sector: Healthcare

Employees: 5

Address: 7800 Susquehanna St., Pittsburgh, PA 15208

Phone: 412-894-1853

Last updated: 2024-12-31

Passage Bio, Inc.

Passage Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

PBGM01, PBFT02, PBKR03, PBML04, PBAL05, PBCM06

Passage Bio, Inc. develops transformative therapies for central nervous system diseases using proprietary genetic medicine technologies to deliver functional genes for the treatment of various disorders.

Tags: AAVhu68, central nervous system, genetic medicines, proprietary technology, therapies

Symbol: PASG

Recent Price: $0.67

Industry: Biotechnology

CEO: Dr. William Chou M.D.

Sector: Healthcare

Employees: 58

Address: One Commerce Square, Philadelphia, PA 19103

Phone: 267 866 0311

Leadership

  • William Chou, MD, President and Chief Executive Officer
  • Kathleen Borthwick, Chief Financial Officer
  • Sue Browne, PhD, Chief Scientific Officer
  • Edgar B. (Chip) Cale, General Counsel and Corporate Secretary
  • Eden Fucci, SVP Technical Operations
  • Stuart Henderson, Chief Business Officer
  • Karl Whitney, PhD, SVP Global Regulatory Affairs
  • James M. Wilson, MD, PhD, Scientific Advisor
  • Maxine Gowen, PhD, Chairwoman
  • Athena Countouriotis, MD,
  • Derrell D. Porter, MD,
  • Dolan Sondhi, PhD,
  • Sandip Kapadia,
  • Tom Kassberg,
  • Saqib Islam,
  • Samiah Al-Zaidy, MD, Vice President, Clinical Development
  • Andrea Campanile, Vice President, Clinical Operations

Last updated: 2024-12-31

Alto Neuroscience, Inc.

Alto Neuroscience, Inc. logo
Market Cap: Low
Employees: Low

ALTO-100, ALTO-300, ALTO-101, ALTO-203, ALTO-202

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company specializing in psychiatry drug development, with a range of innovative treatments targeting major depressive disorder and cognitive impairments.

Tags: AI-enabled biomarker, MDD, biopharmaceutical, cognitive impairment, drug development, psychiatry, schizophrenia

Symbol: ANRO

Recent Price: $4.20

Industry: Biotechnology

CEO: Dr. Amit Etkin M.D., Ph.D.

Sector: Healthcare

Employees: 78

Address: 369 South San Antonio Road, Los Altos, CA 94022

Phone: (650) 200-0412

Last updated: 2024-12-31

Alzamend Neuro, Inc.

Alzamend Neuro, Inc. logo
Market Cap: Lowest
Employees: Lowest

AL001 and AL002

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing products for neurodegenerative and psychiatric disorders. Their pipeline includes AL001 for Alzheimer's and psychiatric disorders, and AL002 for Alzheimer's disease using a novel vaccine approach.

Tags: Alzheimer's, biopharmaceutical, clinical trials, mental health, neurodegenerative disorders, psychiatric disorders

Symbol: ALZN

Recent Price: $1.20

Industry: Biotechnology

CEO: Mr. Stephan Jackman

Sector: Healthcare

Employees: 4

Address: 3500 Lenox Road NE, Atlanta, GA 30326

Phone: 844 722 6333

Last updated: 2024-12-31

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Medium

AMX0035

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their leading product, AMX0035, is aimed at ALS treatment.

Tags: ALS, AMX0035, biopharmaceutical, neurodegenerative diseases, therapeutics

Symbol: AMLX

Recent Price: $3.84

Industry: Biotechnology

CEO: Mr. Joshua B. Cohen

Sector: Healthcare

Employees: 384

Address: 43 Thorndike Street, Cambridge, MA 02141

Phone: 617 682 0917

Leadership

  • Linda A. Arsenault, Chief Human Resources Officer
  • Camille L. Bedrosian, MD, Chief Medical Officer
  • Josh Cohen, Co-CEO & Co-Founder
  • James M. Frates, Chief Financial Officer
  • Tom Holmes, Chief Technical Operations Officer
  • Justin Klee, Co-CEO & Co-Founder
  • Gina M. Mazzariello, Chief Legal Officer & General Counsel
  • Rudolph Tanzi, PhD, Founding Chair of the Amylyx SAB
  • Wally Gilbert, Special Advisor
  • Kari Firestone, Director
  • Paul Fonteyne, Director
  • George Milne, Chairman
  • Daphne Quimi, Director
  • Bernhardt G. Zeiher, MD, FACP, FCCP, Director

Last updated: 2024-12-31

180 Life Sciences Corp.

180 Life Sciences Corp. logo
Market Cap: Lowest
Employees: Lowest

Therapeutics for chronic pain, inflammation, fibrosis, and inflammatory diseases

1180 Life Sciences Corp. is a clinical-stage biotechnology company focused on developing therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis, using platforms such as fibrosis and anti-TNF, synthetic CBD analogs, and a7n ACh R.

Tags: CBD analogs, a7n ACh R, anti-TNF, biotechnology, chronic pain, clinical-stage, fibrosis, inflammation, therapeutics

Symbol: ATNF

Recent Price: $2.98

Industry: Biotechnology

CEO: Mr. Lloyd Blair Jordan L.L.B., M.B.A.

Sector: Healthcare

Employees: 4

Address: Building 4, Palo Alto, CA 94306

Phone: 650 507 0669

Last updated: 2024-11-08

Belite Bio, Inc

Belite Bio, Inc logo
Market Cap: High
Employees: Lowest

LBS-008

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics for age-related macular degeneration and Stargardt diseases. Its lead product candidate, LBS-008, is in phase 3 clinical trials.

Tags: Stargardt diseases, biopharmaceutical, clinical-stage, drug development, liver disease, macular degeneration, phase 3, therapeutics

Symbol: BLTE

Recent Price: $61.97

Industry: Biotechnology

CEO: Dr. Yu-Hsin Lin M.B.A., Ph.D.

Sector: Healthcare

Employees: 20

Address: 5820 Oberlin Drive, San Diego, CA 92121

Phone: 858-246-6240

Last updated: 2024-12-31

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. logo
Market Cap: Highest
Employees: Medium

CAPLYTA

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing novel drugs for the treatment of neuropsychiatric and neurologic diseases targeting intracellular signaling in the central nervous system. Key products include CAPLYTA for schizophrenia and ongoing developments in treatments for bipolar depression, autism spectrum disorder, and more.

Tags: biopharmaceutical, bipolar depression, central nervous system, drug development, neurologic diseases, neuropsychiatric, schizophrenia

Symbol: ITCI

Recent Price: $83.48

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. Sharon Mates Ph.D.

Sector: Healthcare

Employees: 610

Address: 430 East 29th Street, New York, NY 10016

Phone: 646 440 9333

Leadership

  • Sharon Mates, Ph.D., Chairman, Founder & Chief Executive Officer
  • Michael I. Halstead, J.D., President
  • Mark Neumann, Executive Vice President, Chief Commercial Officer
  • Suresh Durgam, M.D., Executive Vice President, Chief Medical Officer
  • Sanjeev Narula, Executive Vice President, Chief Financial Officer
  • John A. Bardi, Senior Vice President, Market Access, Policy and Government Affairs
  • Robert E. Davis, Ph.D., Senior Vice President, Chief Scientific Officer
  • Karen Sheehy, Esq., Senior Vice President and Chief Compliance Officer
  • Michael Olchaskey, Pharm.D., Senior Vice President, Head of Regulatory Affairs
  • Juan Sanchez, M.D., Vice President of Corporate Communications and Investor Relations
  • Willie R. Earley, M.D., Senior Vice President, Head of Clinical Development
  • Joel S. Marcus, J.D., CPA, Executive Chairman & Founder
  • Rory B. Riggs, MBA, Co-Founder and Director
  • E. Rene Salas, CPA, Former Senior Client Partner at Ernst & Young, LLP; Former CFO, Wellstat, LLC
  • Robert L. Van Nostrand, Chairman, Metabolix; Board Member, Achillion Pharmaceuticals; Former CFO, OSI Pharmaceuticals

Last updated: 2024-12-31

Lantern Pharma Inc.

Lantern Pharma Inc. logo
Market Cap: Lowest
Employees: Lowest

LP-100

Lantern Pharma Inc. is a clinical stage biotechnology company focused on using artificial intelligence, machine learning, and genomic data to streamline drug development, with key drug candidates including LP-100, LP-300, and LP-184 for various cancer treatments.

Tags: artificial intelligence, biotechnology, cancer treatment, drug development, genomic data, machine learning

Symbol: LTRN

Recent Price: $3.27

Industry: Biotechnology

CEO: Mr. Panna Sharma PH.D.

Sector: Healthcare

Employees: 21

Address: 1920 McKinney Avenue, Dallas, TX 75201

Phone: 972 277 1136

Last updated: 2024-12-31

Neurogene Inc.

Neurogene Inc. logo
Market Cap: Medium
Employees: Low

NGN-401, NGN-101

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.

Tags: Rett syndrome, biotechnology, gene therapy, genetic medicines, life sciences, neurological diseases, neuronal ceroid lipofuscinosis

Symbol: NGNE

Recent Price: $22.28

Industry: Biotechnology

CEO: Dr. Rachel L. McMinn Ph.D.

Sector: Healthcare

Employees: 91

Address: 535 W 24th Street, New York, NY 10011

Phone: (877) 237-5020

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Palisade Bio, Inc.

Palisade Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

LB1148

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing oral therapies targeting serious diseases related to the breakdown of the gastrointestinal mucosal barrier. Their lead product, LB1148, is designed to protect gut integrity during intestinal stress.

Tags: LB1148, biopharmaceutical, clinical-stage, gastrointestinal health, mucosal barrier, oral therapies

Symbol: PALI

Recent Price: $1.70

Industry: Biotechnology

CEO: Mr. J. D. Finley

Sector: Healthcare

Employees: 9

Address: 5800 Armada Drive, Carlsbad, CA 92008

Phone: 858 704 4900

Last updated: 2024-12-31

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. logo
Market Cap: High
Employees: Medium

AG10, BBP-265, BBP-831, BBP-631, Encaleret

Bridge Bio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases, with a pipeline of 30 programs including candidates like AG10, BBP-265, and others in various stages of clinical trials.

Tags: biopharmaceuticals, clinical trials, drug development, genetic diseases

Symbol: BBIO

Recent Price: $27.32

Industry: Biotechnology

CEO: Dr. Neil Kumar Ph.D.

Sector: Healthcare

Employees: 550

Address: 421 Kipling Street, Palo Alto, CA 94301

Phone: 650 391 9740

Last updated: 2024-12-31

Denali Therapeutics Inc.

Denali Therapeutics Inc. logo
Market Cap: High
Employees: Medium

BIIB122/DNL151

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. Its pipeline includes treatments for Parkinson's disease, hunter syndrome, ALS, multiple sclerosis, and Alzheimer's disease. It collaborates with companies such as Takeda Pharmaceutical Company and Genentech, Inc.

Tags: ALS, Alzheimer's disease, Parkinson's disease, biopharmaceutical, hunter syndrome, multiple sclerosis, neurodegenerative diseases

Symbol: DNLI

Recent Price: $20.24

Industry: Biotechnology

CEO: Dr. Ryan J. Watts Ph.D.

Sector: Healthcare

Employees: 364

Address: 161 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 866 8548

Last updated: 2024-12-31

Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010

Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.

Tags: ALS, Parkinson's disease, Sanfilippo syndrome, biopharmaceutical, central nervous system, major depressive disorder, respiratory disorders, therapeutics

Symbol: SEEL

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Raj Mehra J.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 300 Park Avenue, New York, NY 10022

Phone: 646 293 2100

Last updated: 2024-12-31